Similarly, the phase 2 trial by Jones et al. (2020) provided evidence of improved progression-free survival with the combination of fulvestrant and capivasertib in metastatic estrogen receptor-positive breast cancer, compared to placebo [3]. Here, ESR1 is linked to breast carcinoma.